VIA
FATE icon

Vident Investment Advisory’s Fate Therapeutics FATE Stock Holding History

Vident Investment Advisory’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-58,045
Closed -$331K – 1235
2023
Q1 		$331K Buy
58,045
+2,821
+5% +$17K 0.01% 920
2022
Q4 		$557K Buy
55,224
+20,274
+58% +$381K 0.02% 671
2022
Q3 		$723K Sell
34,950
-812
-2% -$23.5K 0.02% 681
2022
Q2 		$886K Buy
35,762
+13,540
+61% +$374K 0.03% 661
2022
Q1 		$862K Buy
22,222
+3,716
+20% +$144K 0.02% 750
2021
Q4 		$1.08M Buy
18,506
+2,023
+12% +$115K 0.03% 673
2021
Q3 		$977K Sell
16,483
-1,178
-7% -$92.4K 0.03% 686
2021
Q2 		$1.53M Buy
17,661
+841
+5% +$67.8K 0.05% 510
2021
Q1 		$1.39M Sell
16,820
-69
-0.4% -$6.61K 0.05% 516
2020
Q4 		$1.54M Sell
16,889
-24,781
-59% -$1.54M 0.06% 393
2020
Q3 		$1.67M Sell
41,670
-2,910
-7% -$102K 0.08% 301
2020
Q2 		$1.53M Sell
44,580
-32,314
-42% -$963K 0.08% 305
2020
Q1 		$1.71M Sell
76,894
-4,801
-6% -$121K 0.11% 217
2019
Q4 		$1.6M Buy
81,695
+1,274
+2% +$20.2K 0.1% 319
2019
Q3 		$1.25M Sell
80,421
-2,298
-3% -$44.1K 0.11% 141
2019
Q2 		$1.68M Sell
82,719
-13,596
-14% -$245K 0.14% 101
2019
Q1 		$1.69M Sell
96,315
-3,479
-3% -$54.9K 0.09% 316
2018
Q4 		$1.28M Sell
99,794
-94,906
-49% -$1.32M 0.07% 367
2018
Q3 		$3.17M Sell
194,700
-12,976
-6% -$153K 0.12% 215
2018
Q2 		$2.35M Buy
+207,676
New +$2.29M 0.09% 296

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Vident Investment Advisory's FATE Position: Q2 2023 in Review

Vident Investment Advisory sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 58,045 shares — an estimated $331K sold.

Vident Investment Advisory first reported a position in FATE in Q2 2018 and held it in 20 quarters. The position peaked at $3.17M in Q3 2018. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • Vident Investment Advisory reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 58,045 Fate Therapeutics shares in Q2 2023, an estimated $331K.
  • Vident Investment Advisory first reported a position in Fate Therapeutics in Q2 2018 and held it in 20 quarters.
  • Vident Investment Advisory's Fate Therapeutics position peaked at $3.17M in Q3 2018.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.